A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00700427 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2017

Enrollment

INDUSTRY

Sponsor class

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

DRUG: atomoxetine hydrochloride
DRUG: Placebo

Sponsor

Eli Lilly and Company